DexCom Executive Vice President Sells $107,168 in Shares

Michael Jon Brown reduces his stake in the medical device company by 1.51%

Apr. 17, 2026 at 10:33am

Got story updates? Submit your updates here. ›

A highly detailed, macro-level view of the intricate inner components and mechanisms of a medical device, conveying the complex engineering and precision behind DexCom's continuous glucose monitoring systems.The sophisticated machinery powering DexCom's innovative glucose monitoring technology reflects the company's commitment to medical innovation.San Diego Today

DexCom, Inc. (NASDAQ:DXCM) Executive Vice President Michael Jon Brown sold 1,700 shares of the company's stock on April 15th, 2026 at an average price of $63.04 per share, resulting in a total transaction of $107,168. The sale represented a 1.51% decrease in Brown's position, leaving him with 111,204 shares valued at approximately $7,010,300.

Why it matters

Insider transactions, such as this sale by a DexCom executive, can provide insights into management's views on the company's prospects and valuation. While a single transaction does not necessarily indicate a broader trend, it is still noteworthy when a high-level insider reduces their stake, as it may signal a change in their outlook or a desire to diversify their personal holdings.

The details

Michael Jon Brown, the Executive Vice President of DexCom, sold 1,700 shares of the company's stock on April 15th, 2026. The shares were sold at an average price of $63.04, resulting in a total transaction value of $107,168. Following the sale, Brown now directly owns 111,204 shares of DexCom stock, valued at approximately $7,010,300.16.

  • On April 15th, 2026, Michael Jon Brown sold 1,700 shares of DexCom stock.
  • On March 16th, 2026, Michael Jon Brown sold 1,700 shares of DexCom stock.

The players

Michael Jon Brown

The Executive Vice President of DexCom, Inc.

DexCom, Inc.

A medical device company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for people with diabetes.

Got photos? Submit your photos here. ›

What they’re saying

“The trade was a 1.51% decrease in their position.”

— Michael Jon Brown, Executive Vice President

What’s next

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which means the sale was part of a predetermined trading strategy and not based on any inside information.

The takeaway

This insider sale by a DexCom executive, while not necessarily indicative of a broader trend, is still noteworthy as it represents a reduction in his personal stake in the company. Investors may want to monitor any further insider transactions to gauge management's confidence in the company's future performance.